Par Drugs And Chemicals Limited (PAR) - Net Assets

Latest as of March 2026: Rs1.12 Billion INR ≈ $12.11 Million USD

Based on the latest financial reports, Par Drugs And Chemicals Limited (PAR) has net assets worth Rs1.12 Billion INR (≈ $12.11 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs1.29 Billion ≈ $13.97 Million USD) and total liabilities (Rs172.28 Million ≈ $1.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PAR goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs1.12 Billion
% of Total Assets	86.67%
Annual Growth Rate	20.5%
5-Year Change	87.02%
10-Year Change	483.15%
Growth Volatility	10.97

Par Drugs And Chemicals Limited - Net Assets Trend (2016–2026)

This chart illustrates how Par Drugs And Chemicals Limited's net assets have evolved over time, based on quarterly financial data. See Par Drugs And Chemicals Limited defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Par Drugs And Chemicals Limited (2016–2026)

The table below shows the annual net assets of Par Drugs And Chemicals Limited from 2016 to 2026. For live valuation and market cap data, see PAR market cap.

Year	Net Assets	Change
2026-03-31	Rs1.12 Billion ≈ $12.11 Million	+13.14%
2025-03-31	Rs989.75 Million ≈ $10.70 Million	+15.58%
2024-03-31	Rs856.32 Million ≈ $9.26 Million	+20.21%
2023-03-31	Rs712.38 Million ≈ $7.70 Million	+18.97%
2022-03-31	Rs598.77 Million ≈ $6.48 Million	+14.68%
2021-03-31	Rs522.15 Million ≈ $5.65 Million	+28.56%
2020-03-31	Rs406.15 Million ≈ $4.39 Million	+39.49%
2019-03-31	Rs291.17 Million ≈ $3.15 Million	+40.67%
2018-03-31	Rs206.99 Million ≈ $2.24 Million	+7.79%
2017-03-31	Rs192.03 Million ≈ $2.08 Million	+10.65%
2016-03-31	Rs173.56 Million ≈ $1.88 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Par Drugs And Chemicals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs123.05 Million	10.99%
Other Components	Rs996.80 Million	89.01%
Total Equity	Rs1.12 Billion	100.00%

Par Drugs And Chemicals Limited Competitors by Market Cap

The table below lists competitors of Par Drugs And Chemicals Limited ranked by their market capitalization.

Company	Market Cap
Zacatecas Silver Corp V:ZAC	$12.84 Million
Tellusgruppen AB ST:TELLUS	$12.85 Million
Salutica Bhd KLSE:0183	$12.87 Million
Emova Group SA PA:ALEMV	$12.88 Million
PATERSON RESOURCES LTD F:U40	$12.83 Million
Biovie Inc NASDAQ:BIVI	$12.82 Million
Taoping Inc NASDAQ:TAOP	$12.82 Million
Strategic Resources Inc V:SR	$12.81 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Par Drugs And Chemicals Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 989,749,000 to 1,119,846,000, a change of 130,097,000 (13.1%).
Net income of 131,086,000 contributed positively to equity growth.
Other comprehensive income decreased equity by 685,999.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs131.09 Million	+11.71%
Other Comprehensive Income	Rs-686.00K	-0.06%
Other Changes	Rs-303.00K	-0.03%
Total Change	Rs-	13.14%

Book Value vs Market Value Analysis

This analysis compares Par Drugs And Chemicals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.06x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 6.83x to 1.06x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-03-31	Rs14.11	Rs96.40	x
2017-03-31	Rs15.61	Rs96.40	x
2018-03-31	Rs16.82	Rs96.40	x
2019-03-31	Rs23.66	Rs96.40	x
2020-03-31	Rs33.03	Rs96.40	x
2021-03-31	Rs42.49	Rs96.40	x
2022-03-31	Rs48.66	Rs96.40	x
2023-03-31	Rs57.90	Rs96.40	x
2024-03-31	Rs69.59	Rs96.40	x
2025-03-31	Rs80.47	Rs96.40	x
2026-03-31	Rs90.98	Rs96.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Par Drugs And Chemicals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 11.71%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 12.65%
• Asset Turnover: 0.80x
• Equity Multiplier: 1.15x
Recent ROE (11.71%) is below the historical average (12.27%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	2.43%	1.27%	0.57x	3.34x	Rs-13.14 Million
2017	9.62%	3.96%	0.83x	2.92x	Rs-725.30K
2018	7.22%	3.56%	0.78x	2.61x	Rs-5.75 Million
2019	8.31%	5.30%	0.89x	1.76x	Rs-4.93 Million
2020	11.73%	8.65%	0.92x	1.48x	Rs7.04 Million
2021	22.24%	19.39%	0.78x	1.46x	Rs63.90 Million
2022	15.39%	12.35%	0.95x	1.31x	Rs32.26 Million
2023	15.91%	11.92%	1.07x	1.25x	Rs42.10 Million
2024	16.93%	15.16%	0.94x	1.19x	Rs59.38 Million
2025	13.50%	13.23%	0.85x	1.21x	Rs34.60 Million
2026	11.71%	12.65%	0.80x	1.15x	Rs19.10 Million

Industry Comparison

This section compares Par Drugs And Chemicals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $41,118,163,484
Average return on equity (ROE) among peers: 13.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Par Drugs And Chemicals Limited (PAR)	Rs1.12 Billion	2.43%	0.15x	$12.83 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$366.97 Million	3.51%	2.41x	$25.11 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.23 Billion	12.93%	2.27x	$365.36 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.31 Million	-8.08%	0.08x	$645.54 Million
Abbott India Limited (ABBOTINDIA)	$2.31 Billion	29.62%	0.43x	$6.01 Billion
Ajanta Pharma Limited (AJANTPHARM)	$32.64 Billion	21.83%	0.24x	$4.15 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$7.23 Billion	13.11%	3.52x	$996.26 Million
Alkem Laboratories Limited (ALKEM)	$75.58 Billion	20.97%	0.52x	$6.95 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.09 Billion	18.92%	0.29x	$170.62 Million
Alembic Pharmaceuticals Limited (APLLTD)	$22.20 Billion	18.58%	0.77x	$1.59 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$268.52 Billion	7.18%	0.49x	$8.98 Billion

About Par Drugs And Chemicals Limited

NSE:PAR India Drug Manufacturers - Specialty & Generic

Market Cap

$12.83 Million

Rs1.19 Billion INR

Market Cap Rank

#26415 Global

#1470 in India

Share Price

Rs96.40

Change (1 day)

+1.62%

52-Week Range

Rs78.58 - Rs118.56

All Time High

Rs348.45